文献速递艾滋病与性传播感染

从三药抗逆转录病毒方案转换为多替拉韦加拉米夫定后的血浆多组学效应

Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

DOLAM 试验显示,病毒学抑制的 HIV 感染者从三药方案转换为多替拉韦加拉米夫定二药方案后 48 周病毒学非劣效,但体重增加。本次对血浆进行非靶向蛋白质组学、代谢组学和脂质组学分析,发现转换后 N-乙酰胞壁酰-L-丙氨酸酰胺酶、胰岛素样生长因子结合蛋白 3、丙氨酸和甘油三酯(48:0)的血浆浓度出现多组学改变,这些分子变化可能涉及炎症免疫通路及脂质和糖代谢,但临床意义尚不确定,需进一步研究确认。

要点

  • DOLAM 试验中转换为多替拉韦加拉米夫定二药方案后 48 周病毒学非劣效,但体重增加。
  • 转换后血浆 N-乙酰胞壁酰-L-丙氨酸酰胺酶、胰岛素样生长因子结合蛋白 3、丙氨酸和甘油三酯(48:0)浓度出现多组学改变。
  • 这些分子变化可能与炎症免疫通路及脂质和糖代谢相关,但临床意义尚不确定。

核心结论

  • 非靶向多组学分析发现,从三药方案转换为多替拉韦加拉米夫定二药方案后,血浆中 N-乙酰胞壁酰-L-丙氨酸酰胺酶、胰岛素样生长因子结合蛋白 3、丙氨酸和甘油三酯(48:0)出现分子改变,这些改变可能与炎症免疫通路及脂质和糖代谢相关,但临床意义尚不确定,需进一步研究确认并评估长期临床后果。

研究设计与样本

  • DOLAM(EudraCT 201500027435)是一项 4 期、随机、开放标签、非劣效性试验,病毒学抑制的 HIV 感染者按 1:1 分配至转换为多替拉韦加拉米夫定二药方案组或继续三药方案组,随访 48 周。
  • 在基线和 48 周时进行非靶向蛋白质组学、代谢组学和脂质组学分析,采用单变量和多变量分析识别两治疗组间关键分子的变化。

主要发现

  • 从三药方案转换为二药方案后,血浆 N-乙酰胞壁酰-L-丙氨酸酰胺酶(Q96PD5)、胰岛素样生长因子结合蛋白 3(A6XND0)、丙氨酸和甘油三酯(48:0)的循环浓度出现多组学改变。
  • 相关分析显示,在接受二药方案治疗者中这四种分子的上调之间存在关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出这些改变的临床意义尚不确定。
  • 原文指出需要进一步工作来确认这些发现并评估其长期临床后果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR) was virologically non-inferior to continuing 3DR after 48 weeks of follow-up. Weight increased with 2DR relative to 3DR but it did not impact on metabolic parameters. METHODS: Multiomics plasma profile was performed to gain further insight into whether this therapy switch might affect specific biological pathways. DOLAM (EudraCT 201500027435) is a Phase 4, randomized, open-label, non-inferiority trial in which virologically suppressed persons with HIV treated with 3DR were assigned (1:1) to switch to 2DR or to continue 3DR for 48 weeks. Untargeted proteomics, metabolomics and lipidomics analyses were performed at baseline and at 48 weeks. Univariate and multivariate analyses were performed to identify changes in key molecules between both therapy arms. RESULTS: Switching from 3DR to 2DR showed a multiomic impact on circulating plasma concentration of N-acetylmuramoyl-L-alanine amidase (Q96PD5), insulin-like growth factor-binding protein 3 (A6XND0), alanine and triglyceride (TG) (48:0). Correlation analyses identified an association among the up-regulation of these four molecules in persons treated with 2DR. CONCLUSIONS: Untargeted multiomics profiling studies identified molecular changes potentially associated with inflammation immune pathways, and with lipid and glucose metabolism. Although these changes could be associated with potential metabolic or cardiovascular consequences, their clinical significance remains uncertain. Further work is needed to confirm these findings and to assess their long-term clinical consequences.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. de Lazzari E, Negredo EB, Domingo P, et al. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. J Antimicrob Chemother. 2024. PMID: 38546974. doi:10.1093/jac/dkae083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。